|Class Period:||Jul-23-14 to May-13-15|
|Lead Plaintiff Deadline:||Aug-7-15|
|Court:||Central District of California|
The action alleges that the Company and its executives violated federal securities laws during the Class Period by failing to disclose that (1) the Company' New Drug Application (NDA) filing for neratinib would be purposed toward a positive early stage breast cancer indication as opposed to the previously announced metastatic breast cancer; (2) the Company will need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which the Company does not possess; (3) the required additional studies would push the timeline for filing the NDA into at least the first quarter of 2016; and (4) the Company overstated results from its Phase III ExteNET Trial. Puma Biotechnology, Inc. (NYSE:PBYI) has 32.15 million outstanding shares with market capitalization of 4.46 Billion and its share price finished at $138.79 by plunging -3.78% in last traded session. As the returns are concern, return on equity was recorded -95.70% .
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.